Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Daniel Weiss, M.D.
Schrödinger, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- the University of Kansas Clinical Research Center
Fairway, Kansas, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Cleveland Clinic Foundation
Cleveland, Ohio, United States
- the Ohio State University Wexner Medical Center - James Cancer Hospital
Columbus, Ohio, United States
- Oncology Associates of Oregon, P.C.
Eugene, Oregon, United States
- Oregon Health & Science University - Knight Cancer Institute - Center of Hematologic Malignancies
Portland, Oregon, United States
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization
Philadelphia, Pennsylvania, United States
- Tristar Bone Marrow Transplant, Llc
Nashville, Tennessee, United States
- St. David'S South Austin Medical Center
Austin, Texas, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Sept 2023
- Primary completion
- 14 Aug 2025
- Completion
- 9 Sept 2025
- Last update posted
- 22 Sept 2025
- Registered enrollment
- 66
- Registry id
- NCT05961839
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.